55 / 64
REUNIÓN 5
47
5. Escolar Albadalejo G, García Frade J, Lopez Fernandez MF, Roldan Schillling V. Guía
sobre los nuevos anticoagulantes orales. Disponible en:
http://www.sehh.es/es/documentos/guias-y-documentos/1747-guia-sehh-seth-para-el-manejo-de-los-nue-
vos-anticoagulantes-orales.html
6. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, et al.
Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor
Concentrates: Significance of Studies In Vitro with Circulating Human Blood. PLoS ONE.
2013;8:e78696. doi:10.1371/journal.pone.0078696.
7. Schiele F,Van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al.A specific antidote
for dabigatran: functional and structural characterization. Blood. 2013;121:3554-62.
8. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ,Abe K, Lee G, et al.A specific antidote
for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor
Xa. Nat Med. 2013;19:446-51.
9. Dolgin E. Antidotes edge closer to reversing effects of new blood thinners. Nat Med.
2013;19:251.